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Abstract
Background/objectives Cystic ﬁbrosis (CF) is characterized by excessive activation of immune processes. The aim of this
study was to evaluate the effect of synbiotic supplementation on the inﬂammatory response in children/adolescents with CF.
Subjects/methods A randomized, placebo-controlled, double-blind, clinical-trial was conducted with control group (CG, n
= 17), placebo-CF-group (PCFG, n= 19), synbiotic CF-group (SCFG, n= 22), PCFG negative (n= 8) and positive (n=
11) bacteriology, and SCFG negative (n= 12) and positive (n= 10) bacteriology. Markers of lung function (FEV1),
nutritional status [body mass index-for age (BMI/A), height-for-age (H/A), weight-for-age (W/A), upper-arm fat area (UFA),
upper-arm muscle area (UMA), body fat (%BF)], and inﬂammation [interleukin (IL)-12, tumor necrosis factor-alpha (TNF-
α), IL-10, IL-6, IL-1β, IL-8, myeloperoxidase (MPO), nitric oxide metabolites (NOx)] were evaluated before and after 90-
day of supplementation with a synbiotic.
Results No signiﬁcance difference was found between the baseline and end evaluations of FEV1 and nutricional status
markers. A signiﬁcant interaction (time vs. group) was found for IL-12 (p= 0.010) and myeloperoxidase (p= 0.036)
between PCFG and SCFG, however, the difference was not maintained after assessing the groups individually. NOx
diminished signiﬁcantly after supplementation in the SCFG (p= 0.030). In the SCFG with positive bacteriology, reductions
were found in IL-6 (p= 0.033) and IL-8 (p= 0.009) after supplementation.
Conclusions Synbiotic supplementation shown promise at diminishing the pro-inﬂammatory markers IL-6, IL-8 in the
SCFG with positive bacteriology and NOx in the SCFG in children/adolescents with CF.
Introduction
A massive continuous inﬂux of neutrophils occurs during
inﬂammation of the airways in cystic ﬁbrosis (CF) [1], as a
consequence there is the release of chemokines [2].
When an imbalance occurs in the intestinal microbiota,
can lead to the pro-inﬂammatory cytokines release. This, in
turn, leads to the secretion of chloride/water ion by the
intestinal epithelium, which can cause inﬂammation, tissue
damage, and diarrhea [3].
The prebiotic fructooligosaccharides (FOS) has been
associated with the improvement in symptoms and the
composition of intestinal microbiota [4] and, in irritable
bowel syndrome, FOS regulates the immune system [5].
Probiotic bacteria, such as Lactobacillus (L.) paracasei, L.
rhamnosus, and L. acidophilus, have been associated with
antimicrobial activity [6], reduction in tissue damage caused
by tumor necrosis factor-alpha (TNF-α) [7], reduction in the
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production of interleukin (IL)-8 [8], the induction in the
production of IL-108 and immunomodulation of dendritic
cells [8]. Biﬁdobacterium (B) lactis has been associated
with an improvement in the function of the intestinal barrier
and the attenuation of inﬂammation [9].
Prebiotics and probiotics can contribute to the treatment
of CF once the patients are exposed to broad-spectrum
antibiotics such as trobamycin and colistin [10] and, have
increased intestinal permeability and abnormal microbiota
[11].
The aim of this study was to evaluate the effect of syn-
biotic supplementation (FOS, L. paracasei, L. rhamnosus,
L. acidophilus, and B. lactis) on markers of the systemic
inﬂammatory response in children and adolescents with CF.
Subjects and methods
Study design
A randomized, placebo-controlled, double-blind trial was
conducted between October/2014–June/2016 at the Joana
de Gusmão Children’s Hospital, Florianópolis/SC/Brazil.
Approval by the Human Research Ethics Committees at the
Federal University of Santa Catarina (#48959715.2.
1001.0121), and is registered—Brazilian Registry of Clin-
ical Trials (RBR-5BYRSC). The statement of informed
consent was sign for the legal guardians of the children and
adolescents.
Subjects
The non-probabilistic, convenience sample was composed of
72 children and adolescents allocated to a control group (CG,
n= 17, mean age: 8.55± 3.03 years), placebo CF group
(PCFG, n= 19, mean age: 10.74± 2.54 years) and synbiotic
CF group (SCFG, n= 22, mean age: 9.59± 2.79 years). The
patients with CF were also divided into a negative bacter-
iology group (absence of pathogenic microorganisms for CF)
and positive bacteriology group [presence of one or more
pathogenic microorganisms: Pseudomonas (P) aeruginosa,
Staphylococcus (S) aureus, and Burkholderia (B) cepacia]
according to the supplement ingested. The inclusion criteria
for the CG were ≥ 1– ≤ 16 years of age and an absence of
CF. The individuals in the PCFG and SCFG needed to have
a diagnosis of CF (chloride sweat test ≥60mmol/L) and be
clinically stable for at least 30 days prior to the data col-
lection process [12]. The exclusion criteria for all groups
were described previously [12]. The individuals in the PCFG
and SCFG were evaluated at baseline and after 90-day per-
iod, allocated to the different groups through a block ran-
domization process and stratiﬁed by sex and age (Research-
Randomizer-Form v4.0-Lancaster/Pennsylvania/USA).
Assessment of dietary intake
The dietary intake was determined using a validated semi-
quantitative food frequency questionnaire according to the
age group [13, 14] and analyzed using the food composition
table (USDA/Washington/DC/USA) [15]. Daily supple-
mentation and enzyme as part of the protocol [16, 17] was
taken into account and the supplement intake was deter-
mined on the basis of patient reports.
Dietary supplementation
Synbiotic supplementation consisted of a combination of
FOS (5.5 g/day) and four probiotic strains (108–109 CFU/
day each strain): L. paracasei, L. rhamnosus, L. acid-
ophilus, and B. lactis (Lactofos®-SKL-Functional-Nutri-
tion-São Paulo/SP/Brazil). Maltodextrin (Maison-de-La-
Santé®-Florianópolis/SC/Brazil) was the placebo. The syn-
biotic and placebo were offered in six-gram packets in the
form of powder. The habitual diet was maintained, but with
restrictions regarding the consumption of foods containing
prebiotics and probiotics in the 90-day period. Tolerance to
the synbiotic was assessed based on the occurrence of
gastrointestinal symptoms (nausea, vomiting, excessive
ﬂatulence, abdominal distension, intestinal gurgling, and
abdominal pain) and fecal consistency.
Assessment of clinical and bacteriological, lung
function, and disease severity
Clinical evaluation was obtained through the medical
records of patients during the study. The information col-
lected was about steatorrhea and diarrhea presence. A
bacteriological determination and the lung function [asses-
sed by Forced Expiratory Volume in 1 s (FEV1)] were
described previously [12]. Disease severity was determined
based on the Shwachman-Kulczycki (S-K score) [12].
Assessment of nutritional status
Anthropometric data were collected following the criteria of
the World Health Organization (WHO) [18]. Weight was
determined with a digital scale (BK50F-Balmak®-Santa-
Bárbara-d’Oeste/SP/Brazil) and height was measured using
a stadiometer (Alturaexata®-Belo-Horizonte/MG/Brazil).
Nutritional status was classiﬁed based on the WHO [18]
criteria using z-scores for height-for-age (z-H/A), weight-
for-age (z-W/A) and body mass index-for-age (z-BMI/A).
Triceps, biceps, sub-scapular, and supra-iliac skin folds
thickness (TSF, BSF, SSSF, and SISF, respectively) were
measured using the Lange skinfold caliper®-Beta Technol-
ogy Incorporated (Santa-Cruz/California/USA) [18]. The
percentage of body fat (%BF) was determined based on the
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sum of the four skinfold thickness measures (BSF, TSF,
SSSF, and SISF) adjusted for sex and age group. Mid-up
arm circumference (AC) was measured with a non-elastic
tape for the calculation of upper-arm muscle area (UMA).
The method proposed by Frisancho [19] was used for the
determination of upper-arm fat area (UFA) and UMA; these
measures were also expressed in z-scores (Siscres-Growth-
and-Development-Program-Campinas/SP/Brazil).
Analysis of inﬂammatory markers
Serum concentrations of IL-12, TNF-α, IL-10, IL-6, and IL-
8 were determined using ﬂow cytometry using commercial
Cytometric Bead Array inﬂammatory cytokine kit in a
FACS Canto II ﬂow cytometer both from BD-Biosciences®-
San Diego/CA/USA, with the aid of the Cell Quest-Pro
software program. Standard curves for each cytokine were
plotted and the concentrations of each test sample were
calculated using the FCAP array program v.1.0.2 (BD-
Biosciences®-Osasco/SP/Brazil). MPO activity was eval-
uated using the colorimetric method ELISA (Organon-
Tecknica®-Roseland/New-Jersey/USA) [20] and nitric
oxide metabolites (NOx) was determined using the Griess
reaction [21]. The concentration of high-sensitivity C-
reactive protein was determined based on nephelometry
using the CardioPhase®-hs-CRP reagent and BN® II
equipment (Siemens-Healthcare-Diagnostics- Tarrytown/
New-York/USA). The white blood cell count was analyzed
using a semi-automated method with the aid of the Heco 5
Table 1 Demographic, clinical, nutritional, and inﬂammatory markers of the control group (CG), cystic ﬁbrosis group (CFG): CFG placebo and
CFG supplemented with symbiotic
Variables CG CFG (n= 41) p-value
(n= 17) Placebo CFG (n= 19) Synbiotic CFG (n= 22)
Demographic/clinical
Age (years)a,b 8.55± 3.03 10.74± 2.54 9.59± 2.79 0.071
Sex (n,% Male) 6 (35.3) 10 (52.6) 12 (54.5) —
S-K score (points)a,c NA 81.88± 16.02 82.78± 8.70 0.885
FEV1 (%)
d,e NA 74.44 (51.20–97.01) 88.86 (58.55–97.00) 0.855
Energy intaked,e
Energy (kcal) NA 2727.09 (2336.47–3476.16) 2586.46 (1844.21–3094.71) 0.214
Nutritional statusb
z-BMI/Aa 0.22± 1.36f −1.21± 1.12g −0.58± 1.22f,g o0.001
z-H/Aa −0.32± 1.14f −1.03± 1.23g −0.78± 1.34g,h 0.005
z-W/Aa −0.03± 1.24f −1.89± 0.92g −0.67± 1.09f,h 0.003
z-UFAa −0.33± 1.12f −0.73± 0.89g −0.51± 1.02g,h 0.007
z-UMA (z-score)a −0.32± 1.63f −1.69± 1.14g −1.25± 0.87f,g 0.004
BF (%)a 23.50± 7.05f 14.26± 4.88g 15.98± 5.87g,h o0.001
Inﬂammatory markers
NOx (µmol/L)a,b 34.16± 8.84 39.37± 17.26 43.64± 17.38 0.178
hs-CRP (mg/L)d,i 0.27 (0.18–0.39)f 2.15 (1.80–24.70)g 1.30 (1.00–3.55)g o0.001
TNF-α (pg/mL)d,i 0.53 (0.47–0.73)f 0.47 (0.29–1.37)g 0.41 (0.00–1.16)g 0.505
Lymphocytes (cells/mm3× 103)a,b 2.934± 1.646 3.041± 0.955 3.267± 0.981 0.708
Monocytes (cells/mm3)a,b 381.00 (297.50–475.25)f 724.00 (553.00–1175.00)g 733.00 (576.50–855.00)g o0.001
S-K score Shwachman-Kulczycki score, NA not applicable, FEV1 forced expiratory volume in 1 s, Nutritional status in z-escore:BMI/A body mass
index-for age, H/A height-for-age, W/A weight-for-age, UFA upper-arm fat area, UMA upper-arm muscle area, and %BF body fat percentage, NOx
nitric oxide metabolites, hs-CRP high-sensitivity C-reactive protein, TNF-α tumor necrosis factor-alpha
a Values expressed as mean± standard deviation
b ANOVA test and post-hoc Bonferroni test
ct-student test
d Values expressed as median (interquartile range 25°–75° percentile)
e Mann–Whitney test
i Kruskal–Wallis test and post-hoc Mann–Whitney test (p o 0.05)
f,g,h Same letter has no difference
Bold text indicates a statistically signiﬁcance with a p-value less than 0.05
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Plus equipment (Radim-Company®-Pomezia/Rome/Italy)
[22].
Statistical analysis
The Shapiro–Wilk test was used to determine the normality
of the data. Differences among the CG, PCFG and SCFG
were analyzed using either analysis of variance or the
Kruskal–Wallis test followed by Bonferroni and
Mann–Whitney post-hoc tests, respectively. Data with non-
Gaussian distribution were submitted to logarithmic nor-
malization. Sphericity and homogeneity of the data were
evaluated using Mauchly’s test and Levene’s test, respec-
tively. Changes in markers of lung function, nutritional
status, and inﬂammation following supplementation (pla-
cebo or synbiotic) and over time (ﬁnal-baseline) were ana-
lyzed using a repeated-measures generalized linear model to
determine the possible effect of an interaction between the
intra-subject and inter-subjects factor on the dependent
variable. The analyses were adjusted for sex, age, and
energy intake. Due to missing data, intention-to-treat ana-
lysis included a principal analysis using multiple imputa-
tions. Five sets of imputed data were created using the
following prediction variables: sex, age, FEV1, H/A, BMI/I,
BF, UMA, UFA, MPO, NOx, IL-12, TNF-α, IL-10, IL-6,
IL-1β, and IL-8. The effect size was calculated using
Cohen’s d (d) adjusted for use in repeated measurements
and for the removal of bias from small samples in the
estimates of standardized effects [23]. Effect sizes were
assumed as trivial (o0.20), small (between 0.20 and 0.49),
medium (between 0.50 and 0.79) or large (40.80) [23].
Cohen’s d effect size was calculated using an effect size
calculator (http://www.sportsci.org/index.html). Statistical
analysis: SPSS v16.0 for WindowsTM and p-value o0.05
was considered indicative of statistical signiﬁcance.
Table 2 Lung function, nutritional status, and inﬂammatory markers in patients with cystic ﬁbrosis (CF) supplemented with placebo (CF) group or
synbiotic (CF) group
Variables Placebo CF group (PCFG) (n= 19) Synbiotic CF group (SCFG) (n= 22)
Before After p-value Before After p-value Interaction time vs. groupa (p-value)
Lung functionb
FEV1 (%) 73.58± 22.28 77.39± 21.76 0.427 80.25± 23.87 75.99± 20.78 0.306 0.696
Nutritional statusb
z-BMI/Ab −1.21± 1.12 −1.20± 1.29 0.943 −0.58± 1.22 −0.68± 1.13 0.120 0.589
z-H/Ab −1.03± 1.23 −0.87± 1.43 0.449 −0.78± 1.34 −0.66± 1.24 0.497 0.380
z-W/Ab −1.98± 1.29 −1.79± 1.31 0.515 −0.67± 1.10 −0.88± 1.22 0.276 0.443
z-UFAb −0.73± 0.89 −0.74± 0.99 0.980 −0.51± 1.02 −0.59± 0.90 0.374 0.544
z-UMAb −1.70± 1.11 −1.34± 1.12 0.073 −1.25± 0.86 −1.21± 1.28 0.813 0.425
BF (%)b 14.41± 4.79 14.78± 4.18 0.624 15.98± 5.87 16.05± 4.97 0.419 0.644
Inﬂammatory markersb,c
IL-12 (pg/mL) 0.68± 0.83 −0.04± 0.45 0.842 0.32± 0.54 0.49± 0.90 0.250 0.010
TNF-α (pg/mL) −0.03± 0.70 −0.22± 0.91 0.916 −0.02± 0.78 −0.40± 1.33 0.125 0.759
IL-10 (pg/mL) 0.32± 0.50 0.18± 0.50 0.495 0.35± 0.56 0.13± 0.74 0.056 0.561
IL-6 (pg/mL) 1.04± 0.55 0.77± 0.77 0.158 0.71± 0.49 0.48± 0.45 0.074 0.540
IL-1β (pg/mL) 0.43± 0.65 −0.28± 1.02 0.446 0.23± 0.59 0.02± 0.84 0.321 0.486
IL-8 (pg/mL) 1.57± 0.38 1.46± 0.52 0.187 1.54± 0.25 1.41± 0.37 0.053 0.583
MPO (mU/mL) 6.65± 0.29 6.47± 0.40 0.321 6.56± 0.19 6.52± 0.17 0.532 0.036
NOx (µmol/L) 3.68± 0.40 3.36± 0.67 0.319 3.71± 0.38 3.44± 0.38 0.030 0.400
Values expressed as mean± standard deviation
FEV1 forced expiratory volume in 1 s, Nutritional status in z-score:BMI/A body mass index-for age, H/A height-for-age, W/A weight-for-age, UFA
upper-arm fat area, UMA upper-arm muscle area, and %BF body fat percentage, IL-12 interleukin 12, TNF-α tumor necrosis factor-alpha, IL-10
interleukin-10, IL-6 interleukin 6, IL-1β interleukin-1beta, IL-8 interleukin 8, MPO myeloperoxidase, NOx nitric oxide metabolites
aRepeated-measures generalized linear model with adjustment for age, sex and energy intake with evaluation of the interaction between type of
supplement (placebo or synbiotic) and supplementation time (After–Before) (p o 0.05)
bRepeated-measures generalized linear model with adjustment for age and sex
cValues were normalized by log10 transformation
Bold text indicates a statistically signiﬁcance with a p-value less than 0.05
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Results
Characterization of sample
During the study all participants were clinically stable, had
no steatorrhea and/or maldigestion, and were using enzymes
according to the recommendations of the Clinical Practice
Guidelines [17]. Regarding pathogenic bacteria, 57.9% of
the patients in the PCFG and 45.5% in the SCFG were
colonized by one or more bacteria. The most prevalent were
S. aureus (47.7%) and B. cepacea (21.1%) in the PCFG as
well as S. aureus (18.2%), and P. aeruginosa (22.7%) in the
SCFG.
The male sex predominated in the PCFG and SCFG and
the female sex predominated in the CG (64.7%). Both
groups of patients had high mean S-K scores (PCFG: 81.88
± 16.02%, SCFG: 82.78± 8.70%). General physical status
was classiﬁed as either excellent or good in 75% of the
PCFG and 88.9% of the SCFG and there were no classiﬁ-
cations of severe CF. PCFG and SCFG had mean FEV1
values ≥ 70% in the classiﬁcation of pulmonary obstruction
(p= 0.885) (Table 1).
The energy consumption between PCFG and SCFG were
similar, with no signiﬁcant difference (p= 0.214) (Table 1).
Regarding the markers of nutritional status, z-BMI/A, z-
H/A, z-W/A, z-UFA, z-UMA, and %BF differed sig-
niﬁcantly between the CG and patient groups (p o 0.05),
with no signiﬁcant difference between the PCFG and
SCFG. The patient groups differed signiﬁcantly from one
another only with regard to z-W/A (Table 1).
Signiﬁcant differences in the inﬂammatory response
markers CRP and monocytes were found when the PCFG
and SCFG when compared to CG (p o 0.001) (Table 1).
Effect of synbiotic on markers of lung function and
nutritional status
No signiﬁcant difference and interactions were found
between group (PCFG and SCFG) and time (ﬁnal-baseline)
of FEV1 (Table 2). Likewise, when the groups were sub-
divided into negative and positive bacteriology (Tables 3
and 4).
Regarding nutritional status, increases were found in %
BF (SCFG: 15.98± 5.87% vs. 16.05± 4.97%; SCFG with
Table 3 Lung function, nutritional status, and inﬂammatory markers in patients with cystic ﬁbrosis supplemented with placebo (CFG
supplemented with placebo) according to the absence or presence of pathogenic microorganisms
Variables Placebo CFG negative bacteriology (n= 8) Placebo CFG positive bacteriology (n= 11)
Before After p-value Before After p-value
Lung functiona
FEV1 (%) 87.78± 36.89 90.00± 27.73 0.709 77.96± 23.83 68.75± 29.75 0.296
Nutritional statusa
z-BMI/Aa −1.36± 0.97 −1.02± 0.93 0.565 −1.05± 1.58 −1.26± 1.55 0.425
z-H/Aa −1.32± 1.42 −1.27± 1.41 0.132 −0.51± 1.28 −0.44± 1.31 0.416
z-W/Aa −2.20± 1.30 −1.82± 1.19 0.073 −1.97± 1.23 −1.74± 1.44 0.643
z-UFAa −0.87± 0.86 −0.81± 0.88 0.852 −0.28± 0.86 −0.61± 0.82 0.071
z-UMAa −1.79± 1.22 −1.47± 1.16 0.278 −1.36± 1.26 −1.29± 1.17 0.843
BF (%)a 13.54± 4.63 14.42± 4.35 0.995 15.86± 5.25 15.36± 4.88 0.616
Inﬂammatory markersa,b
IL-12 (pg/mL) 0.28± 0.78 0.14± 0.33 0.781 0.82± 1.05 0.01± 0.38 0.765
TNF-α (pg/mL) −0.84± 0.78 −0.38± 0.39 0.466 0.89± 0.04 0.01± 0.93 0.677
IL-10 (pg/mL) 0.31± 0.26 0.12± 0.33 0.892 0.36± 0.55 0.25± 0.48 0.828
IL-6 (pg/mL) 1.04± 0.74 0.62± 0.65 0.133 1.05± 0.33 0.91± 0.74 0.357
IL-1β (pg/mL) 0.06± 0.65 −0.38± 0.86 0.940 0.92± 0.04 −0.13± 1.40 0.904
IL-8 (pg/mL) 1.57± 0.43 1.55± 0.50 0.999 1.57± 0.26 1.38± 0.39 0.188
MPO (mU/mL) 6.62± 0.27 6.49± 0.27 0.466 6.69± 0.23 6.45± 0.29 0.730
NOx (µmol/L) 3.64± 0.41 3.40± 0.29 0.279 3.71± 0.42 3.32± 0.79 0.462
Values expressed as mean± standard deviation
FEV1 forced expiratory volume in 1 s, Nutritional status in z-score: BMI/A body mass index-for age, H/A height-for-age, W/A weight-for-age, UFA
upper-arm fat area, UMA upper-arm muscle area, and %BF body fat percentage, IL-12 interleukin 12, TNF-α tumor necrosis factor-alpha, IL-10
interleukin-10, IL-6 interleukin 6, IL-1β interleukin-1beta, IL-8 interleukin 8, MPO myeloperoxidase, NOx nitric oxide metabolites
aRepeated-measures generalized linear model with adjustment for age, sex, and energy intake. Signiﬁcance of p o 0.05
bValues were normalized by log10 transformation
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positive bacteriology: 14.66± 5.87% vs. 15.35± 4.58%),
UMA (SCFG: −1.25± 0.86 z-score vs. −1.21± 1.28 z-
score; SCFG with negative bacteriology: −1.18± 0.77 z-
score vs. −1.07± 1.49 z-score), and z-BMI/A (SCFG with
positive bacteriology: −0.85± 1.27 z-score vs. −0.76±
1.25 z-score), but the difference did not achieve statistical
signiﬁcance (Table 4).
Effect of synbiotic on inﬂammatory markers
In the evaluation of supplement and time, a statistically
signiﬁcant interaction was found with regard to inﬂamma-
tory markers IL-12 (p= 0.010) and MPO (p= 0.036).
When analyzing the effect of each supplement individually
no signiﬁcant differences and an important effect size were
found. The NOx diminished signiﬁcantly after supple-
mentation with the synbiotic in the SCFG (p= 0.030, d=
0.79) (Table 2).
The pro-inﬂammatory cytokines IL-6 (d= 0.42), IL-1β
(d= 0.39), and IL-8 (d= 0.35) diminished following sup-
plementation in the SCFG, but the differences did not
achieve statistical signiﬁcance (Table 2). In the individual
analysis of the effect of the synbiotic in the SCFG with
positive bacteriology, signiﬁcant decrease were found for
IL-6 (0.91 ± 0.52 pg/mL vs. 0.45± 0.49 pg/mL, d= 0.72)
and IL-8 (1.47 ± 0.23 pg/mL vs. 1.35± 0.18 pg/mL, d=
0.58) (Table 4).
In the SCFG negative and positive bacteriology, the NOx
decrease were not signiﬁcant, however, it had a medium
effect size (p= 0.070, d= 0.74; p= 0.542, d= 0.75,
respectively) (Table 4).
Discussion
The results regarding the characterization of the sample
corroborate previous studies that evaluated pulmonary
function, nutritional status, and inﬂammatory markers of CF
patients in relation to non-CF controls. In general, this
population presents a compromise of the pulmonary func-
tion and consequently of the nutritional state, already hav-
ing been shown a relation between both factors [24–27].
Table 4 Lung function, nutritional status, and inﬂammatory markers in patients with cystic ﬁbrosis supplemented with synbiotic (CFG
supplemented with synbiotic) according to the absence or presence of pathogenic microorganisms
Variáveis Synbiotic CFG negative bacteriology (n= 12) Synbiotic CFG positive bacteriology (n= 10)
Before After p-value Before After p-value
Lung functiona
FEV1 (%) 83.36± 16.70 77.18± 19.93 0.618 75.60± 33.25 74.21± 23.83 0.303
Nutritional statusa
z-BMI/Aa −0.19± 1.25 −0.49± 1.15 0.102 −0.85± 1.27 −0.76± 1.25 0.427
z-H/Aa −1.02± 1.24 −0.91± 1.18 0.316 −0.44± 1.36 −0.49± 1.31 0.189
z-W/Aa −0.95± 1.04 −1.09± 1.05 0.237 −0.15± 1.11 −0.52± 1.47 0.484
z-UFAa −0.28± 1.00 −0.48± 0.72 0.683 −0.80± 0.01 −0.80± 0.89 0.616
z-UMAa −1.18± 0.77 −1.07± 1.49 0.942 −1.33± 1.00 −1.37± 1.01 0.889
BF (%)a 17.09± 5.89 16.63± 5.43 0.450 14.66± 5.87 15.35± 4.58 0.729
Inﬂammatory markersa,b
IL-12 (pg/mL) 0.19± 0.14 0.71± 1.09 0.192 0.49± 0.70 0.22± 0.55 0.909
TNF-α (pg/mL) −0.41± 0.34 −0.80± 1.05 0.266 −0.19± 0.92 −0.22± 1.06 0.847
IL-10 (pg/mL) 0.34± 0.30 −0.00± 0.37 0.085 0.50± 0.53 0.37± 0.57 0.458
IL-6 (pg/mL) 0.51± 0.40 0.52± 0.45 0.473 0.91± 0.52 0.45± 0.49 0.033
IL-1β (pg/mL) 0.04± 0.17 0.00± 0.46 0.985 0.13± 0.86 0.79± 0.56 0.200
IL-8 (pg/mL) 1.59± 0.28 1.50± 0.40 0.925 1.47± 0.23 1.35± 0.18 0.009
MPO (mU/mL) 6.50± 0.17 6.54± 0.12 0.756 6.56± 0.18 6.52± 0.18 0.314
NOx (µmol/L) 3.74± 0.38 3.47± 0.53 0.070 3.86± 0.46 3.54± 0.42 0.542
Values expressed as mean± standard deviation
FEV1 forced expiratory volume in 1 s, Nutritional status in z-score: BMI/A body mass index-for age, H/A height-for age, W/A weight-for age, UFA
upper-arm fat area, UMA upper-arm muscle area, and %BF body fat percentage, IL-12 interleukin 12, TNF-α tumor necrosis factor-alpha, IL-10
interleukin-10, IL-6 interleukin 6, IL-1β interleukin-1beta, IL-8 interleukin 8, MPO myeloperoxidase, NOx nitric oxide metabolites
aRepeated-measures generalized linear model with adjustment for age, sex and energy intake. Signiﬁcance of p o 0.05
bValues were normalized by log10 transformation
Bold text indicates a statistically signiﬁcance with a p-value less than 0.05
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Regarding the inﬂammatory process, in the present study,
patients with CF also showed an increase in the con-
centration of pro-inﬂammatory markers [12].
Studies addressing the use of synbiotic or probiotic
supplementation in CF are scarce, offer conﬂicting results
and employ different methodological designs, with differ-
ences in the age of the participants, markers evaluated and
analysis techniques. However, the use of these supplements
in the prevention or treatment of pulmonary exacerbation
and lowered the frequency of hospital admissions of CF has
been proposed [28]. In the present study, no signiﬁcant
difference between the PCFG and SCFG with positive or
negative bacteriology was found on lung function measured
by FEV1. Likewise in a study involving 61 adolescents and
adults with CF (median age: 17.5 years; interquartile range:
6 to 29 years) given a supplement with the probiotic L.
reuteri (1010 CFU) for 6 months. Although, the authors
found a signiﬁcant reduction in the number of lung
exacerbations and upper airway respiratory infections
among patients with mild to moderate lung disease [29].
Even as in a study involving 10 adults with CF (mean age:
26.2± 12.9 years) given a supplement of probiotics (L.
acidophilus, L. bulgaricus, B. biﬁdum, Streptococcus ther-
mophilus) for 6 months, the authors also found a signiﬁcant
reduction in the number lung exacerbations (1.3 ± 1.0 to
0.6± 0.7, p= 0.002) [11]. In contrast, in a study involving
38 adolescents with CF (mean age: 13.2± 4.2 years) given
a supplement with L. GG for 6 months, a signiﬁcant
increase in FEV1 was found (3.6 ± 5.2% vs. 0.9± 5%, p=
0.020). The authors hypothesizes this improvement in FEV1
as the consequence of the increase in weight and reduction
in the number of lung exacerbations found during the study
[10].
The synbiotic and/or duration of supplementation were
not sufﬁcient to affect the nutritional status of the partici-
pants in the present study independently of positive or
negative bacteriology. A similar ﬁnding is reported in a
previous study analyzing the effect of supplementation with
probiotics (L. acidophilus, L. bulgaricus, B. biﬁdum, and S.
thermophilus) for 6 months on BMI [11]. However, in
another study evaluating supplementation with the probiotic
L. GG for 6 months, a signiﬁcant increase in weight was
found in patients with CF in comparison to those who only
received an oral hydration solution (1.5 ± 1.8 kg and 0.7±
1.8 kg, respectively, p= 0.020) and the authors suggest that
the increase in weight may have been associated with the
reduction in the number of lung exacerbations [10].
In the present study, there was no improvement in
nutritional status and lung function, which may be related to
shorter supplementation time, considering that some of the
strains used, as well as the amount of them, resemble pre-
vious studies [10, 11] that found a signiﬁcant improvement.
Regarding the inﬂammatory markers IL-12 and MPO in
the SCFG, the signiﬁcant interaction found that when
assessed individually was not maintained, may be due to
biological changes not related to supplementation that
occurred during the study with the participants, because at
the baseline moment no signiﬁcant differences were found
between the placebo and synbiotic groups.
The synbiotic evaluated in this study led to a signiﬁcant
reduction in serum levels of NOx (p o 0.030, d= 0,79) in
the SCFG. As well the synbiotic had a medium effect on
NOx in the SCFG negative and positive bacteriology, that it
was ‘‘likely to be perceived’’ according to Cohen’s statistics
[23]. Measure NO is difﬁcult due to short half-life, how-
ever, measure the serum levels of NOx is accepted, because
it has a high correlation with the NO endogenous produc-
tion [30, 31]. As seen previously NOx levels are high in the
circulation system of individuals with CF [12], which may
be a consequence of an increase in NO production through
induced nitric oxide synthase (iNOS) [32]. Its production is
triggered by activated macrophages, TNF-α and IL-1β and,
in excess, can cause tissue damage [32].
After supplementation with the synbiotic in the present
study, the cytokine IL-1β underwent a reduction, which,
although non-signiﬁcant, may be related to the reduction in
NOx levels and consequent attenuation of the inﬂammatory
process.
The reduction, albeit non-signiﬁcant, in concentrations of
the inﬂammatory markers IL-6 and IL-8 in the SCFG may
also be an indication of the effectiveness of the synbiotic at
attenuating the pro-inﬂammatory response. This effect was
evident when the PCFG and SCFG were stratiﬁed based on
bacteriology (negative and positive), as individuals in the
SCFG with positive bacteriology sowed a signiﬁcant
reduction in these markers (IL-6: p= 0.033, d= 0.72; IL-8:
p= 0.009, d= 0.58 for). The authors of a study evaluating
the effect of supplementation with the probiotic L. GG for
6 months found no signiﬁcant difference in the level of IL-8
in the sputum of patients with CF [11]. Likewise, the
authors of a study evaluating the effect of supplementation
with L. reuteri found no difference in levels of IL-6 or IL-8
in the feces of patients [33].
The comparison of studies is hampered by the use of
different methods for the evaluation of the IL-6 and IL-8.
Investigations report an increase in these pro-inﬂammatory
markers in patients with CF, especially in groups with
positive bacteriology as well as those with positive results
for P. aeruginosa in the blood and bronchial epithelial cells
[12, 34]. Like TNF-α and IL-1β, the cytokines IL-6 and IL-
8, are mediators of the acute phase. In an inﬂammatory
process, IL-1β and TNF-α can induce the synthesis of these
cytokines by macrophages and epithelial cells [35]. The
synthesis of IL-8 by epithelial cells of the airways in an
endogenous manner or in response to pathogens through the
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activation of nuclear factor kappa B plays a central role in
the physiopathology of inﬂammation in CF [1].
The effects of the synbiotic on the biomarkers assessed in
this study may have been limited due to the time of sup-
plementation as well as due to the evaluation methods used.
The serum evaluation of inﬂammatory markers, unlike
some studies evaluated in the gastrointestinal tract, were
performed with the objective of evaluating synbiotic effects
in a systemic way. Although the alterations found are small,
the long-term effect that the synbiotic can have should be
considered. Another limitation of this study, we did not
evaluate the inﬂammatory markers in the gastrointestinal
tract. As strengths we have the study design, sample size
considering the difﬁculty of adherence to supplementation
in this population and the precision of the methods used.
In conclusion, strategies are needed to attenuate inﬂam-
matory process in order to diminish the consequent lung
damage and negative inﬂuence on the nutritional status of
patients. Supplementation with the synbiotic tested in the
present investigation shown promise at diminishing the pro-
inﬂammatory markers IL-6, IL-8, and NOx in children and
adolescents with cystic ﬁbrosis. However, further studies
with a longer evaluation period are needed to gain a better
understanding of the effects of synbiotic dietary supple-
ments in this population.
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